Actively Recruiting

Phase Not Applicable
Age: 18Years - 38Years
FEMALE
NCT07396181

Standardization of Variable Conditions of Embryo Transfer Into the Uterine Cavity in the Procedure of Medically Assisted Procreation in Humans

Led by Przychodnia Lekarska nOvum Katarzyna Kozioł, Piotr Lewandowski sp.k. · Updated on 2026-04-13

200

Participants Needed

1

Research Sites

91 weeks

Total Duration

On this page

Sponsors

P

Przychodnia Lekarska nOvum Katarzyna Kozioł, Piotr Lewandowski sp.k.

Lead Sponsor

F

Fundusze Europejskie dla Mazowsza 2021-2027 (FEMA.01.01-IP.01-04WN/24)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The EFECT study is a clinical trial designed to determine whether improving the consistency of embryo transfer procedures can increase pregnancy success in patients undergoing frozen embryo transfer (cryoET). While laboratory techniques for fertilization, embryo culture, and selection have advanced significantly, the process of transferring embryos to the uterus remains variable and depends on small procedural differences, such as temperature changes, mechanical forces, timing, and individual operator techniques. These variations may affect embryo survival and implantation, ultimately influencing pregnancy outcomes. This study tests whether using specialized devices to standardize key aspects of embryo transfer-specifically temperature stability during transport and controlled, precise embryo aspiration and expulsion speed, optimal fluid volume, programmed injection time, elimination of pressure fluctuations and plunger backflow, prevention of embryo re-aspiration and detection of transfer catherer oclusion-can improve pregnancy rates. All embryos in the study are cultured using time-lapse monitoring and selected using artificial intelligence-supported grading, ensuring uniform quality for all participants. The study compares standard manual embryo transfer with transfer using one or both of the devices: Embryocase, which maintains a stable temperature during transport, and Embryopass, which standardizes the procedure and eliminates human factor. A total of 160 participants are randomly assigned to one of four groups: manual transfer without device support, manual transfer with Embryocase, transfer with Embryopass, or transfer with both devices. Participants and outcome assessors are blinded to group assignment, while the staff performing the transfer are aware due to the nature of the devices. All participants receive standard luteal phase support with progesterone following routine clinical practice. The study's main goal is to evaluate whether these procedural improvements lead to higher rates of biochemical pregnancy (positive pregnancy test) and clinical pregnancy (confirmed by ultrasound). Secondary outcomes include implantation rate, live birth rate, device safety, and ease of use as reported by staff. Pregnancy outcomes, including delivery, pregnancy loss, or ectopic pregnancy, are followed until the end of pregnancy. By investigating the impact of procedural standardization, this study aims to determine whether technological improvements during embryo transfer can increase the effectiveness of assisted reproductive treatments. If successful, the results could support the broader adoption of standardized, device-assisted embryo transfer protocols in fertility clinics, helping more patients achieve successful pregnancies.

CONDITIONS

Official Title

Standardization of Variable Conditions of Embryo Transfer Into the Uterine Cavity in the Procedure of Medically Assisted Procreation in Humans

Who Can Participate

Age: 18Years - 38Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient and partner gave written informed consent to participate
  • Underwent IVF or ICSI with all embryos frozen at blastocyst stage, with at least one good quality blastocyst
  • Not currently or recently (last 6 months) participating in another clinical trial
  • Age between 18 and 38 years at screening
  • Body mass index between 18 and less than 30 at screening
  • Both partners have normal infectious tests within 6 months and bacteriological tests within 1 month before embryo transfer
  • Embryo culture performed with time-lapse monitoring and AI grading or placed in EmbryoScope after thawing
  • Normal uterus and endometrium thickness at least 7 mm on embryo transfer day
  • Prepared for cryotransfer in natural or letrozole-induced ovulatory cycle with luteal phase progesterone supplementation
  • On day 5 after ovulation, have at least one thawed, good quality blastocyst
  • Qualified by doctor for embryo transfer procedure on day 5 after ovulation
  • Embryo transfer performed without general anesthesia or additional antispasmodic drugs except routine drotaverine
Not Eligible

You will not qualify if you...

  • Failure to meet inclusion criteria
  • Anatomical abnormalities of uterus or reproductive tract reducing pregnancy chances
  • Diagnosed with endometrial polyps
  • Diagnosed with submucosal or intramural uterine fibroids
  • Diagnosed with fallopian tube hydromas
  • Diagnosed with stage 3 or higher endometriosis
  • Patient or partner carries genetic defects affecting fertility
  • Patient or partner currently or previously treated for cancer affecting fertility
  • Previous unsuccessful embryo transfer with no clinical pregnancy
  • Difficult uterine cavity entry during prior embryo transfer
  • Embryos formed from eggs after polar body biopsy or genetic testing
  • Embryos formed from cryopreserved oocytes
  • Semen obtained by methods other than normal ejaculation
  • Did not use progesterone for luteal phase support
  • Unable to perform embryo transfer on day 5 after ovulation
  • Indications for general anesthesia or pre-transfer antispasmodic procedures/medications other than routine drotaverine
  • Planned incision in areola area before embryo transfer
  • Desire to use Embryoglue for transfer
  • Taking heparin, Clexane, Acesan, or Relanium during or after embryo transfer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Przychodnia Lekarska nOvum Katarzyna Kozioł, Piotr Lewandowski sp.k.

Warsaw, Poland, 02-807

Actively Recruiting

Loading map...

Research Team

K

Katarzyna Kozioł, MD

CONTACT

S

Sylwia Trubacz, mgr inż.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

OTHER

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here